A comprehensive assessment of the risk of bone morphogenetic protein use in spinal fusion surgery and postoperative cancer diagnosis

Kevin S. Cahill, Paul C. McCormick, Allan D Levi

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

The risk of postoperative cancer following the use of recombinant human bone morphogenetic protein (BMP)-2 in spinal fusion is one potential complication that has received significant interest. Until recently, there has been little clinical evidence to support the assertion of potential cancer induction after BMP use in spinal surgery. This report aims to summarize the findings from clinical data available to date from the Yale University Open Data Access (YODA) project as well as more recently published large database studies regarding the association of BMP use in spinal fusion and the risk of postoperative cancer. A detailed review was based on online databases, primary studies, FDA reports, and bibliographies of key articles for studies that assessed the efficacy and safety of BMP in spinal fusion. In an analysis of the YODA project, one meta-analysis detected a statistically significant increase in cancer occurrence at 24 months but not at 48 months, and the other meta-analysis did not detect a significant increase in postoperative cancer occurrence. Analysis of 3 large health care data sets (Medicare, MarketScan, and PearlDiver) revealed that none were able to detect a significant increase in risk of malignant cancers when BMP was used compared with controls. The potential risk of postoperative cancer formation following the use of BMP in spinal fusion must be interpreted on an individual basis for each patient by the surgeon. There is no conclusive evidence that application of the common formulations of BMP during spinal surgery results in the formation of cancer locally or at a distant site.

Original languageEnglish (US)
Pages (from-to)86-93
Number of pages8
JournalJournal of neurosurgery. Spine
Volume23
Issue number1
DOIs
StatePublished - Jul 1 2015

Fingerprint

Spinal Fusion
Bone Morphogenetic Proteins
Neoplasms
Meta-Analysis
Databases
Bone Neoplasms
Bibliography
Medicare
Delivery of Health Care
Safety

Keywords

  • BMP
  • BMP = bone morphogenetic protein
  • cancer
  • IDE = investigational device exemption
  • OHSU = Oregon Health & Science University
  • oncology
  • rhBMP = recombinant human BMP
  • SEER = Surveillance, Epidemiology, and End Results
  • spinal fusion
  • technique
  • YODA = Yale University Open Data Access

ASJC Scopus subject areas

  • Medicine(all)

Cite this

A comprehensive assessment of the risk of bone morphogenetic protein use in spinal fusion surgery and postoperative cancer diagnosis. / Cahill, Kevin S.; McCormick, Paul C.; Levi, Allan D.

In: Journal of neurosurgery. Spine, Vol. 23, No. 1, 01.07.2015, p. 86-93.

Research output: Contribution to journalArticle

@article{c33cbb2e8ee2488cbf5dcc1897357f79,
title = "A comprehensive assessment of the risk of bone morphogenetic protein use in spinal fusion surgery and postoperative cancer diagnosis",
abstract = "The risk of postoperative cancer following the use of recombinant human bone morphogenetic protein (BMP)-2 in spinal fusion is one potential complication that has received significant interest. Until recently, there has been little clinical evidence to support the assertion of potential cancer induction after BMP use in spinal surgery. This report aims to summarize the findings from clinical data available to date from the Yale University Open Data Access (YODA) project as well as more recently published large database studies regarding the association of BMP use in spinal fusion and the risk of postoperative cancer. A detailed review was based on online databases, primary studies, FDA reports, and bibliographies of key articles for studies that assessed the efficacy and safety of BMP in spinal fusion. In an analysis of the YODA project, one meta-analysis detected a statistically significant increase in cancer occurrence at 24 months but not at 48 months, and the other meta-analysis did not detect a significant increase in postoperative cancer occurrence. Analysis of 3 large health care data sets (Medicare, MarketScan, and PearlDiver) revealed that none were able to detect a significant increase in risk of malignant cancers when BMP was used compared with controls. The potential risk of postoperative cancer formation following the use of BMP in spinal fusion must be interpreted on an individual basis for each patient by the surgeon. There is no conclusive evidence that application of the common formulations of BMP during spinal surgery results in the formation of cancer locally or at a distant site.",
keywords = "BMP, BMP = bone morphogenetic protein, cancer, IDE = investigational device exemption, OHSU = Oregon Health & Science University, oncology, rhBMP = recombinant human BMP, SEER = Surveillance, Epidemiology, and End Results, spinal fusion, technique, YODA = Yale University Open Data Access",
author = "Cahill, {Kevin S.} and McCormick, {Paul C.} and Levi, {Allan D}",
year = "2015",
month = "7",
day = "1",
doi = "10.3171/2014.10.SPINE14338",
language = "English (US)",
volume = "23",
pages = "86--93",
journal = "Journal of Neurosurgery: Spine",
issn = "1547-5654",
publisher = "American Association of Neurological Surgeons",
number = "1",

}

TY - JOUR

T1 - A comprehensive assessment of the risk of bone morphogenetic protein use in spinal fusion surgery and postoperative cancer diagnosis

AU - Cahill, Kevin S.

AU - McCormick, Paul C.

AU - Levi, Allan D

PY - 2015/7/1

Y1 - 2015/7/1

N2 - The risk of postoperative cancer following the use of recombinant human bone morphogenetic protein (BMP)-2 in spinal fusion is one potential complication that has received significant interest. Until recently, there has been little clinical evidence to support the assertion of potential cancer induction after BMP use in spinal surgery. This report aims to summarize the findings from clinical data available to date from the Yale University Open Data Access (YODA) project as well as more recently published large database studies regarding the association of BMP use in spinal fusion and the risk of postoperative cancer. A detailed review was based on online databases, primary studies, FDA reports, and bibliographies of key articles for studies that assessed the efficacy and safety of BMP in spinal fusion. In an analysis of the YODA project, one meta-analysis detected a statistically significant increase in cancer occurrence at 24 months but not at 48 months, and the other meta-analysis did not detect a significant increase in postoperative cancer occurrence. Analysis of 3 large health care data sets (Medicare, MarketScan, and PearlDiver) revealed that none were able to detect a significant increase in risk of malignant cancers when BMP was used compared with controls. The potential risk of postoperative cancer formation following the use of BMP in spinal fusion must be interpreted on an individual basis for each patient by the surgeon. There is no conclusive evidence that application of the common formulations of BMP during spinal surgery results in the formation of cancer locally or at a distant site.

AB - The risk of postoperative cancer following the use of recombinant human bone morphogenetic protein (BMP)-2 in spinal fusion is one potential complication that has received significant interest. Until recently, there has been little clinical evidence to support the assertion of potential cancer induction after BMP use in spinal surgery. This report aims to summarize the findings from clinical data available to date from the Yale University Open Data Access (YODA) project as well as more recently published large database studies regarding the association of BMP use in spinal fusion and the risk of postoperative cancer. A detailed review was based on online databases, primary studies, FDA reports, and bibliographies of key articles for studies that assessed the efficacy and safety of BMP in spinal fusion. In an analysis of the YODA project, one meta-analysis detected a statistically significant increase in cancer occurrence at 24 months but not at 48 months, and the other meta-analysis did not detect a significant increase in postoperative cancer occurrence. Analysis of 3 large health care data sets (Medicare, MarketScan, and PearlDiver) revealed that none were able to detect a significant increase in risk of malignant cancers when BMP was used compared with controls. The potential risk of postoperative cancer formation following the use of BMP in spinal fusion must be interpreted on an individual basis for each patient by the surgeon. There is no conclusive evidence that application of the common formulations of BMP during spinal surgery results in the formation of cancer locally or at a distant site.

KW - BMP

KW - BMP = bone morphogenetic protein

KW - cancer

KW - IDE = investigational device exemption

KW - OHSU = Oregon Health & Science University

KW - oncology

KW - rhBMP = recombinant human BMP

KW - SEER = Surveillance, Epidemiology, and End Results

KW - spinal fusion

KW - technique

KW - YODA = Yale University Open Data Access

UR - http://www.scopus.com/inward/record.url?scp=84940905557&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84940905557&partnerID=8YFLogxK

U2 - 10.3171/2014.10.SPINE14338

DO - 10.3171/2014.10.SPINE14338

M3 - Article

VL - 23

SP - 86

EP - 93

JO - Journal of Neurosurgery: Spine

JF - Journal of Neurosurgery: Spine

SN - 1547-5654

IS - 1

ER -